XML 75 R41.htm IDEA: XBRL DOCUMENT v3.25.0.1
Revenue Recognition - Collaboration and License Agreement (Details)
 12 Months Ended 49 Months Ended
Nov. 22, 2020
USD ($)
obligation
program
target
Dec. 31, 2024
USD ($)
target
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2024
USD ($)
target
Nov. 11, 2024
USD ($)
Nov. 30, 2020
USD ($)
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]              
Deferred revenue, revenue recognized   $ 53,438,000 $ 64,120,000        
Unsatisfied performance obligation   59,519,000     $ 59,519,000    
Drug discovery services revenue from contracts with customers   207,539,000 216,666,000 $ 180,955,000      
Drug Discovery Services              
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]              
Drug discovery services revenue from contracts with customers   $ 25,143,000 54,720,000 43,427,000      
BMS | Oncology, Neurology, and Immunology Product              
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]              
Number of specified biological target | target 5            
Number of neurology targets remaining | target   1     1    
Deferred revenue   $ 5,900,000 7,300,000   $ 5,900,000   $ 55,000,000.0
Variable consideration amount   482,000,000.0     482,000,000.0    
Research, development and regulatory milestones, amount $ 257,000,000.0            
Variable consideration, commercial milestones, amount $ 225,000,000.0            
Deferred revenue, revenue recognized         32,000,000.0    
Number of performance obligations | obligation 1            
Number of programs under agreement | program 5            
Unsatisfied performance obligation $ 55,000,000.0            
Drug discovery services revenue from contracts with customers   10,800,000 $ 43,200,000 $ 22,100,000      
Allowance for credit loss, current   0     0    
Novartis Pharma AG | Research, Collaboration and License Agreement | Drug Discovery Services              
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]              
Deferred revenue   150,000,000.0     150,000,000.0    
Variable consideration amount           $ 2,272,000,000  
Research, development and regulatory milestones, amount           892,000,000.0  
Variable consideration, commercial milestones, amount           $ 1,380,000,000  
Deferred revenue, revenue recognized   0          
Novartis Pharma AG | Software Agreement | Drug Discovery Services | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2024-11-12              
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]              
Revenue, remaining performance obligation, expected timing of satisfaction, period           3 years  
Novartis Pharma AG | Collaboration and License Agreement | Drug Discovery Services              
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]              
Deferred revenue   116,700,000     116,700,000    
Drug discovery services revenue from contracts with customers   600,000          
Allowance for credit loss, current   $ 150,000,000.0     $ 150,000,000.0